NDATOPICALGELPriority Review
Approved
Dec 2023
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
4/8 — Partial
Priority Review
Drug data last refreshed 5h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FILSUVEZ is a topical gel containing birch triterpenes approved in December 2023 for wound healing applications. The exact mechanism of action and indication are not publicly specified in available data, but the safety profile suggests dermatological wound management use. This represents a botanical-derived therapeutic approach to an unspecified wound or skin condition.
Growth12.4 years to LOE
Early-stage product in growth phase with minimal competitive pressure creates opportunity for market-building teams, though commercial infrastructure appears nascent.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
A Study to Assess the Incidence of Skin Cancers in Patients With Epidermolysis Bullosa Receiving Filsuvez
Started Dec 2024
580 enrolled
Epidermolysis Bullosa, DystrophicEpidermolysis Bullosa, Junctional
Career Relevance
FILSUVEZ currently shows zero linked job openings, reflecting its very recent approval and limited commercial infrastructure build-out. As a newly launched, patent-protected product with no competitive threats, team growth is expected to accelerate in the coming 12-24 months as Chiesi scales commercial operations.
Brand Manager
Worked on FILSUVEZ at Chiesi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.